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OBJECTIVE: Many conditions have strong diurnal components
which may inﬂuence work productivity. We evaluate the rela-
tionship between sleep impairment and productivity loss using
symptomatic daytime vs. nighttime gastro-esophageal reﬂux
disease (GERD) as an example. METHODS: An Internet survey
of employed US adults measured GERD symptom frequency and
severity (prior 12 months and prior seven days). GERD status
was assessed with the validated GERD-SMQ. General health-
related and GERD-speciﬁc productivity losses were evaluated
using the WPAI questionnaire. Nighttime sleep impairment (SI)
was assessed by a panel of six questions concerning sleep prob-
lems. Our conceptual framework modeled the impact of night-
time symptoms as causing SI which, in turn, inﬂuences daytime
work productivity. Thus, two-equations: 1) SI as a function of
GERD status (and covariates); and 2) WPAI as a function of SI
(and covariates), were simultaneously estimated using three-
stage least squares (3SLS) regression. Results were compared to
those of an alternative instrumental variables speciﬁcation.
RESULTS: Of 65,001 individuals invited to participate, 13,231
(21.4%) responded. A total of 1002 were symptomatic GERD
cases (476 nighttime vs. 526 daytime) which were included in
the analysis. 3SLS showed nighttime vs. daytime GERD was
associated with a signiﬁcant increase in SI (D = 33.6%, p <
0.001). Respondents with severe or very severe GERD also expe-
rienced greater SI (D = 39.1%, p < 0.005). SI was shown to have
a large impact on work productivity (elasticity = 5.4%, p <
0.001). c2 values were 384 (p < 0.0001) and 84.5 (p < 0.0001)
for the ﬁrst and second equations. 3SLS results were consistent
with the IV speciﬁcation. CONCLUSIONS: Nighttime GERD
symptoms signiﬁcantly impair sleep which results in reductions
in daytime work productivity. The impact of the distinct diurnal
nature of chronic conditions is little understood. This framework
may prove useful in evaluating similar chronic health conditions
(eg, asthma) and related adverse events due to medication use.
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OBJECTIVES: To determine whether the Medication Possession
Ratio (MPR) alone or in combination with Breakthrough Events
(BEs), was more likely to differentiate between patients.
METHODS: Medical and prescription claims for MCO enrollees
diagnosed with or receiving therapy for Acid Related Diseases
(ARD) between July 1, 2001 and June 30, 2003 in the Phar-
metrics database were retrieved. Selected for study were persons
over 18 with an ARD diagnosis and a minimum 30 days supply
during the time period for study inclusion. The study classiﬁed
ARD patients by their MPR alone and in combination with spec-
iﬁed BEs into ﬁve cohorts and examined how each classiﬁcation
method was able to correctly differentiate persons based on their
economic data, utilization data, ARD-speciﬁc comorbidities, and
other comorbidities through paired comparison tests. Pairwise
group comparisons were made between cohorts using Bonfer-
roni’s (Dunn’s) method for multiple comparisons of continuous
variables and chi-squared paired comparison tests for discrete
variables. Differences were considered to be statistically signiﬁ-
cant if p <= 0.05. RESULTS: The study identiﬁed a population
of 79,454 persons with 700,846 claims for PPI prescriptions
during the two-year time frame. Overall, the analysis plan iden-
tiﬁed 760 possible matched pair comparisons and 43 compar-
isons between the top two cohorts. The MPR alone method iden-
tiﬁed 523 (68.8%) and the MPR combination method identiﬁed
464 (61.1%) signiﬁcant pairwise comparisons. In comparing the
top two cohorts, the MPR alone method identiﬁed 29 (67.4%)
compared with the combination methods 19 (44.2%). The only
areas where the combination method outperformed the MPR
alone method were for comparing the top two cohorts in terms
of ARD-Speciﬁc comorbidities and for costs in the Emergency
Department. CONCLUSION: The MPR only method outper-
forms the MPR in combination with the existence of BEs at dif-
ferentiating patients with ARD.
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OBJECTIVE: Making process and technology changes in clini-
cal practice is often complex and costly. The interdependence of
processes, staff, technology and patients can bias static models.
Dynamic system simulations can identify problems, and solu-
tions, by imitating actual processes over time. Our objective was
to examine the efﬁciency possible with increased resources in 
an outpatient endoscopy unit using discrete event simulation.
METHODS: We designed a computer simulation model 
(AnylogicTM, AccessTM) of a three procedure room outpatient
endoscopy unit with eight shared preparation/recovery rooms.
Design involved documenting patient and staff ﬂow; determin-
ing process times via observation studies, chart reviews and staff
interviews; and validating output with actual performance data.
The model simulates 20 working days and generates mean daily
statistics. Outcome measures include patient throughput
(patients per day, PPD) and length of stay in minutes (LOS), cal-
culated as mean patient time from arrival to discharge. Scenar-
ios included doubling staff, adding combination responsibility
nurses or adding prep/recovery rooms to the baseline model.
RESULTS: At baseline, the unit averaged 17 PPD, 177 minute
LOS. Outcome statistics for scenarios are (PPD, LOS): doubled
staff (18, 164), one nurse (18, 168), two nurses (18, 166), one
room (19, 184), two rooms (20, 192). Two additional
prep/recovery rooms results in the largest throughput impact (+3
PPD), but increases LOS 15 minutes. The addition of one nurse
results in 98% of the throughput achieved with doubled staff (+1
PPD) and reduces LOS by nine minutes. CONCLUSIONS:
Increasing space capacity results in the largest throughput in this
unit suggesting a potential solution to patient backlogs over time.
However, adding one nurse both increases productivity and
reduces patient LOS. Diminishing marginal returns for increased
nursing units were observed. Further modeling may illuminate
strategies to optimize efﬁciency and proﬁt while also improving
measures of customer satisfaction (i.e., LOS).
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OBJECTIVE: The objective was to investigate whether a former
randomised study (the Nexium One study) reﬂects real-life in
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terms of choice of treatment strategy for longterm treatment of
gastroesophageal reﬂux disease and the associated costs.
METHODS: This study is a follow-up study to the Nexium One
study and is an open observational study in a general practice
setting with 1206 patients. This study was designed as a natu-
ralistic study to emulate a real-life situation as closely as possi-
ble. The observational period was six-months. Three groups of
patients were included in to this study: 1) patients who partici-
pated in the Nexium One trial and were included by general
practionernes (GPs), who participated in the Nexium One trial;
2) patients who did not participate in the Nexium One trial and
were included by GPs, who participated in the Nexium One trial;
and 3) patients who did not participate in the Nexium One trial
and were included by GPs, who did not participate in the
Nexium One trial. As to whether the randomised Nexium One
study reﬂected real-life in terms of treatment and associated
costs, this was investigated by comparing direct medical costs,
total costs for the following patients: A) all patients from the
Nexium One study and B) group three patients (see above).
RESULTS/CONCLUSIONS: A signiﬁcant difference was found
in total costs between group three and all the patients in the
Nexium One study. However, there was no signiﬁcant difference
in direct medical costs. In other words, the Nexium One study
reﬂects real-life costs as there is no difference in the costs of treat-
ment between all patients in the Nexium One study and the
patients, who did not participate in the Nexium One study and
were included by GPs who did not participate in the Nexium
One study.
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OBJECTIVES: To assess the validity and subject acceptability of
electronic data capture (EDC) versions of Irritable Bowel Syn-
drome Quality of Life(IBS-QOL), EuroQoL(EQ-5D) and Work
Productivity and Activity Impairment (WPAI:IBS) question-
naires. METHODS: Comparability of EDC and paper question-
naires was evaluated in 72 subjects with IBS who completed a
baseline EDC or paper questionnaire, a crossover questionnaire
24 hours later, and a retest of the crossover version at week-one.
The EDC version was presented on a hand-held device. Compa-
rability was assessed using paired t-test statistics, intraclass cor-
relation coefﬁcients (ICC) and tests for internal consistency
(Cronbach’s alpha). RESULTS: No signiﬁcant differences were
found between scores obtained by paper questionnaire and EDC
at the baseline and crossover assessments. ICCs between base-
line and crossover assessments ranged from 0.83 to 0.96 for the
IBS-QOL scores, 0.82 to 0.96 for the WPAI:IBS scores, and 0.77
to 0.82 for the EQ-5D. Internal consistency was comparable for
the two data collection methods for the IBS-QOL overall score
(0.96) and subscales and the EQ-5D Index (0.70 vs. 0.74). Retest
statistics (ICC) were generally comparable between the EDC and
paper versions for all scores, as was the relationship between
scores and levels of IBS symptom severity. Ease of use was com-
parable for the two modes of administration, but more patients
preferred EDC (47.2%) than the paper questionnaire (23.6%).
CONCLUSIONS: EDC versions of the IBS-QOL, EQ-5D, and
WPAI:IBS are comparable to paper questionnaires in terms of
internal consistency, test-retest reliability, and discriminant valid-
ity and have greater patient acceptability.
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The impact of treatment on health related quality of life
(HRQoL) in CHB patients is unclear. OBJECTIVE: The objec-
tive of this study was to compare the changes in HRQoL from
baseline, as measured by changes in health status using the
EuroQoL 5 Dimensions (EQ-5D) questionnaire, in patients
receiving ETV or LAM treatment. Utility scores are anchored
between full health (1) and death (0). METHODS: This was a
randomized double blind, double dummy, active controlled trial.
Questionnaires were administered prior to the physician visit at
baseline, Weeks 24 and 48. Mean changes in health index score
(HIS) and visual analog scale (VAS) score from baseline were cal-
culated in all treated patients. Proportions of patients who had
improvement or no change in health dimensions were compared
between the two treatment groups, and patients with missing
Week-48 data were considered failures (NC = F). RESULTS: A
total of 116 of 141 (82%) ETV and 114 of 145 (79%) LAM
patients completed the questionnaires at baseline. Though ETV
patients demonstrated a clinically meaningful improvement in
HIS (0.03) and LAM patients did not (0.01), the difference (0.02)
was not statistically signiﬁcant (p = 0.12). ETV patients had a
trend towards better change in VAS at Week-48 (ETV = 4.13;
LAM = 0.91; mean difference estimate ETV-LAM = 2.11; p =
0.21). A larger proportion of ETV patients had improvement or
no change in all ﬁve health dimensions at Week-48. ETV treat-
ment was superior to LAM in the following dimensions: mobil-
ity; self care; pain or discomfort (94% vs. 82%, p = 0.007; 94%
vs. 85%, p = 0.03; and 90% vs. 77%, p = 0.01, respectively).
CONCLUSION: ETV therapy was associated with greater pro-
portions of patients with improvement or no change in mobil-
ity, self care, and pain or discomfort after 48-weeks of treatment.
ETV patients demonstrated a clinically meaningful improvement
in HIS, and greater improvement in VAS from baseline compared
to LAM.
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OBJECTIVES: To evaluate the impact of tegaserod 6mg b.i.d.
on the quality of life (QoL) of men and women with IBS-C, as
deﬁned by Rome II criteria. METHODS: A multicenter, open-
label, prospective, single-cohort study was conducted in Spain.
Patients entered a one-month, treatment-free, baseline period fol-
lowed by three months’ treatment with tegaserod 6mg b.i.d. and
subsequently, a one-month withdrawal period (no treatment).
QoL was assessed at the end of baseline, treatment and with-
drawal periods using the IBS-QOL; a validated modiﬁed disease-
speciﬁc instrument and the SF-36; a validated generic instrument.
Patients recorded their level of IBS symptom relief in a weekly
diary. Patients were considered responders (R) if ≥two-weeks’
satisfactory relief of global IBS-C symptoms was experienced
